

***Immunization to Prevent Meningococcal Disease:
Yesterday, Today, and Tomorrow***

Symposium for physicians, pharmacists, and nurses while attending the 2008
ICAAC/IDSA Joint Meeting

Activity Date, Time & Location:

Saturday, October 25, 2008

6:00 am – 9:00 am

Grand Hyatt Washington

1000 H Street NW

Constitution AB

Washington, DC 20001

Chairperson:

Lee H. Harrison, MD

Faculty:

Dan M. Granoff, MD

Gregory A. Poland, MD

Sponsored by



This activity has been supported by an educational grant from:



Registration:

Register for this program at <http://PreventMD.cme360.net>

Please bring your registration Confirmation Letter for entrance to the symposium.

Activity Title: *Immunization to Prevent Meningococcal Disease: Yesterday, Today, and Tomorrow*

All inquiries should be directed to:

DIME

222 Merchandise Mart Plaza, Suite 4-160

Chicago, IL 60654

DIMEinfo@DIMedEd.org

www.DiMedEd.org

Target Audience

This activity is targeted to infectious disease specialists, including physicians, nurses, and pharmacists, who attend the 2008 ICAAC/IDSA Joint Meeting.

Activity Purpose

This symposium will address the key learning areas of epidemiology, vaccine strategies, optimization of current approaches, and anticipation of future opportunities for interventions by focusing on the past, present, and future of meningococcal immunization. Because of the identified learning gaps and the diversity of this audience, a broad-based temporal perspective on the prevention of invasive meningococcal disease through immunization is needed. This strategy allows for compelling and cohesive content and will integrate the relevant topics into an activity of interest to providers from different specialties.

Learning Objectives:

- Describe the changing epidemiology of meningococcal disease and its significance to prevention strategies
- Identify current immunization recommendations for meningococcal disease and their rationale in infants, children, adolescents, and adults
- Differentiate the composition, immunogenicity, and safety profiles for current and evolving vaccines used to prevent meningococcal disease

Continuing Medical Education:

Accreditation Statement/Designation Statement

DIME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

DIME designates this educational activity for a maximum of 3.0 *AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.



Continuing Pharmacy Education Statement

DIME is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been assigned the ACPE Universal Program Number 246-000-08-010-L01-P and has been approved for 3.0 contact hours (0.30 CEUs) of continuing education credit.

Continuing Nursing Education

DIME is an approved provider of continuing nursing education by the Illinois Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Participants in this activity are eligible for up to 2.4 contact hours of continuing nursing education.

Statement of Need

Meningococcal disease presents the challenges characteristic of infectious disease, including a shifting epidemiology with risks affecting infants, children, adolescents, adults, and special populations. In adolescents, immunization can prevent meningococcal disease. However, recent data from the Nationwide Inpatient Sample (NIS) show that *Healthy People 2010* goals have not been met for any adolescent immunization effort studied. The Institute of Medicine also recognizes that the US healthcare system is not meeting the needs of adolescents. The Health Plan Employer Data Information Set reports that immunization rates remain low among adolescents, with only 34% having had annual clinic visits for preventive care. Innovative strategies are necessary to identify entry points to care and to encourage the acceptance of immunization in alternative settings. In the 2006 NIS Teen Module, MCV4 coverage was only 11.7% among 13–17 year olds.

These reports and others can guide discussion of potentially effective vaccines, such as a new conjugate vaccine that has been shown to be immunogenic in infants. One review suggests that a vaccine to prevent disease caused by serogroup B meningococci is achievable by novel approaches such as reverse

vaccinology based on *Neisseria* genomic sequencing, recombinant protein technology, and other methods. Despite these advances, prevention can only be achieved if immunization efforts actually reach the appropriate populations. Providers must adhere to the current recommendations of professional societies for educating vaccine-eligible patients and families (and their communities), and for providing vaccinations. A survey of physicians showed that improvement is needed in clinician knowledge of the timing and delivery of immunizations. High-quality educational programs are needed to give clinicians context about the problem, to inform them of trends and advances in vaccine development, and to give them the practical tools and confidence necessary for effective patient education and vaccine delivery.

Disclosures

DIME requires that those involved in the content development and/or presentation of this CME activity disclose to the participant any relevant financial interest or other relationship with (1) the manufacturers of any commercial products or providers of commercial services discussed in an educational presentation and (2) any commercial supporters of the activity.

This CME/CE activity may include discussions regarding the use of medications that may be outside the approved labeling for these products. Physicians should consult the current prescribing information for these products. DIME requires the author to disclose that the product is not labeled for the use under discussion. The provider's documentation of common practices that make the disclosure requirement known to faculty demonstrates compliance with AANP and AAPA guidelines.

Lee H. Harrison, MD

Sources of Funding for Research: Sanofi Pasteur SA

Consulting Agreements: GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corp

Speakers' Bureau/Honorarium Agreements: Novartis Pharmaceuticals Corp; Sanofi Pasteur SA

Financial Interests/Stock Ownership: None

Discussion of Off-Label, Investigational, or Experimental Drug Use: None

Dan M. Granoff, MD

Sources of Funding for Research: Novartis Vaccines; Sanofi Pasteur SA

Consulting Agreements: Novartis Vaccines

Speakers' Bureau/Honorarium Agreements: None

Financial Interests/Stock Ownership: None

Discussion of Off-Label, Investigational, or Experimental Drug Use: Experimental data on meningococcal vaccines under development

Gregory A. Poland, MD

Sources of Funding for Research: Merck & Co., Inc.; Novavax, Inc.; Protein Sciences Corporation

Consulting Agreements: Avianax LLC; CSL Biotheapies; CSL Limited; Emergent Biosolutions, Inc.;

GlaxoSmithKline; Merck & Co., Inc.; Novartis Vaccines; Novavax, Inc.; PowderMed Ltd.

Speakers' Bureau/Honorarium Agreements: None

Financial Interests/Stock Ownership: Novartis Vaccines

Discussion of Off-Label, Investigational, or Experimental Drug Use: None

*Current guidelines state that participants in CME/CE activities should be made aware of any affiliation or financial interest that may affect those involved with content development or presentation. Those involved have completed a Statement of Disclosure, and their names and disclosure information will appear in the activity materials. This information is used to: (1) determine whether a conflict exists, (2) resolve the conflict by initiating a content validation process, and (3) advise learners of this information. Information unavailable at the time of printing will be available for review before the presentation.

*There is no fee for participating in the program or for generation of the certificate.